Liver steatosis with cardiometabolic risk factors (obesity, diabetes, hypertension, dyslipidemia) leading to hepatic and extrahepatic morbidity
Target Population
Adults aged 40-70 years in the UK Biobank cohort
Care Setting
Population-based clinical and research settings with longitudinal follow-up
Key Highlights
MASLD affects approximately 30% of the studied population and is associated with higher prevalence of multimorbidity.
MASLD is linked to increased all-cause mortality (16% higher risk) especially in females and those with fewer long-term conditions.
MASLD is strongly associated with multiple extrahepatic long-term conditions including metabolic, cardiovascular, cancers, kidney, mental/behavioral, and respiratory diseases.
Guideline-Based Recommendations
Diagnosis
Identify MASLD using fatty liver index (FLI) ≥60 combined with presence of cardiometabolic risk factors and low alcohol consumption.
Target cardiometabolic risk factors to reduce liver steatosis and associated multimorbidity.
Address extrahepatic long-term conditions to improve overall outcomes and reduce mortality.
Monitoring & Follow-up
Monitor progression of liver disease spectrum from steatosis to fibrosis and cirrhosis.
Regularly assess for development or worsening of multimorbidity, especially metabolic, cardiovascular, renal, and mental health conditions.
Risks
Increased all-cause mortality associated with MASLD, amplified by presence and number of extrahepatic long-term conditions.
Higher mortality risk particularly noted in females and individuals with low baseline multimorbidity.
Patient & Prescribing Data
Adults with MASLD identified in a large UK cohort with varying degrees of multimorbidity.
Management should focus on comprehensive care addressing both liver disease and associated cardiometabolic and extrahepatic conditions to reduce mortality risk.
Clinical Best Practices
Use validated noninvasive indices like fatty liver index (FLI) for MASLD screening in at-risk populations.
Comprehensively evaluate and manage cardiometabolic risk factors in patients with MASLD.
Screen for and manage multiple extrahepatic long-term conditions to mitigate increased mortality risk.
Recognize sex differences in MASLD impact and tailor interventions accordingly.
Implement longitudinal follow-up to monitor disease progression and multimorbidity development.
A retrospective database study found a low absolute incidence but higher relative hazard of ischemic optic neuropathy following semaglutide initiation.
